Co-Diagnostics の収益と比較して、Dwight Egan の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$39m
Dec 31 2023	US$1m	US$375k	-US$35m
Sep 30 2023	n/a	n/a	-US$43m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$32m
Dec 31 2022	US$2m	US$366k	-US$14m
Sep 30 2022	n/a	n/a	US$15m
Jun 30 2022	n/a	n/a	US$28m
Mar 31 2022	n/a	n/a	US$40m
Dec 31 2021	US$2m	US$350k	US$37m
Sep 30 2021	n/a	n/a	US$42m
Jun 30 2021	n/a	n/a	US$46m
Mar 31 2021	n/a	n/a	US$51m
Dec 31 2020	US$1m	US$309k	US$42m
Sep 30 2020	n/a	n/a	US$28m
Jun 30 2020	n/a	n/a	US$10m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$460k	US$275k	-US$6m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$6m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$474k	US$275k	-US$6m
Sep 30 2018	n/a	n/a	-US$6m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$210k	US$195k	-US$7m

報酬と市場: Dwightの総報酬 ($USD 1.26M ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。

報酬と収益: Dwightの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Dwight Egan (71 yo)

11.2yrs

在職期間

US$1,261,300

報酬

Mr. Dwight H. Egan serves as the Chairman & Chief Executive Officer and was President at Co-Diagnostics, Inc. and has been its Director since April 2013. Mr. Egan has been engaged in private investment bus...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Dwight Egan	Chairman & CEO	no data	US$1.26m	1.17% $ 466.4k
Brian Brown	CFO & Company Secretary	3.3yrs	US$1.04m	0.93% $ 369.2k
Richard Abbott	President	less than a year	データなし	データなし
Brent Satterfield	Co-Founder & Member of Scientific Advisory Board	11.2yrs	US$237.50k	データなし
David Nielsen	Chief Operating Officer	less than a year	データなし	データなし
Dan Bohrer	Vice President of Finance & Accounting	no data	データなし	データなし
Christopher Thurston	Chief Technology Officer	less than a year	データなし	データなし
Andrew Benson	Head of Investor Relations	no data	データなし	データなし
Mayuranki Almaula	Senior Vice President of Overseas Operations & Strategic Alliances	no data	データなし	データなし
Cameron Gundry	Head of Commercialization LATAM/EUR	no data	データなし	データなし
Ivory Chang	Chief Regulatory Affairs Officer	less than a year	データなし	データなし
Seth Egan	Chief Commercialization Officer	less than a year	データなし	データなし

0.3yrs

平均在職期間

50yo

平均年齢

経験豊富な経営陣: CODXの経営陣は経験豊富とはみなされません ( 0.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Dwight Egan	Chairman & CEO	11.2yrs	US$1.26m	1.17% $ 466.4k
Brent Satterfield	Co-Founder & Member of Scientific Advisory Board	2.3yrs	US$237.50k	データなし
Richard Serbin	Independent Director	7.1yrs	US$298.00k	0.38% $ 149.2k
Carl Wittwer	Chairman of Scientific Advisory Board	2.3yrs	データなし	データなし
James Nelson	Independent Director	4.8yrs	US$298.00k	0.37% $ 146.1k
Noriko Kusukawa	Member of Scientific Advisory Board	2.3yrs	データなし	データなし
Edward Murphy	Independent Director	5yrs	US$298.00k	0.41% $ 161.9k
Eugene Durenard	Independent Director	5yrs	US$298.00k	0.37% $ 146.1k
Karen Carroll	Member of Scientific Advisory Board	2.3yrs	データなし	データなし
Anne Wyllie	Member of Scientific Advisory Board	2.3yrs	データなし	データなし

3.5yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: CODXの取締役会は経験豊富であると考えられます ( 3.5年の平均在任期間)。

Co-Diagnostics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Co-Diagnostics, Inc. Appoints Executive Appointments

Chairman exercised options and sold US$58k worth of stock

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

Chairman exercised options and sold US$111k worth of stock

High number of new and inexperienced directors

Recent updates

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Co-Diagnostics, Inc. to Report Q1, 2024 Results on May 09, 2024

Co-Diagnostics, Inc. Appoints Executive Appointments

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Co-Diagnostics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

Chairman exercised options and sold US$58k worth of stock

Consensus revenue estimates increase by 474%

Price target increased by 50% to US$3.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Co-Diagnostics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Consensus revenue estimates fall by 43%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

Co-Diagnostics, Inc. Receives Funding for Co-Dx PCR Home Platform from NIH RADx Tech Program

One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Co-Diagnostics, Inc. to Report Q1, 2023 Results on May 11, 2023

A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Consensus revenue estimates fall by 83%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 16%

Chairman exercised options and sold US$111k worth of stock

Consensus revenue estimates fall by 14%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

Co-Diagnostics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment improved over the past week

Pomerantz Law Firm Announces the Filing of a Class Action Against Co-Diagnostics, Inc. and Certain Officers

Co-Diagnostics: Hold Thesis Remains Well Intact

Investor sentiment deteriorated over the past week

Kaplan Fox & Kilsheimer LLP Files Class Action Suit in the United States District Court for the Southern District of New York Against Co-Diagnostics, Inc

Price target decreased to US$15.33

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes

Co-Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Co-Diagnostics, Inc., Annual General Meeting, Aug 31, 2022

Co-Diagnostics spikes on shipments of monkeypox test

Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Investor sentiment improved over the past week

Now 20% undervalued after recent price drop

Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant

Now 24% undervalued after recent price drop

Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus

Chairman exercised options and sold US$59k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to US$19.33

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Co-Diagnostics: Where's Eikon?

High number of new and inexperienced directors

Consensus EPS estimates increase by 36%

Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Co-Diagnostics: Swinging For The Fences

Investor sentiment deteriorated over the past week

Co-Diagnostics, Inc. (NasdaqCM:CODX) completed the acquisition of Advanced Conceptions, Inc.

Price target decreased to US$19.33

マネジメント基準チェック /24